GW&K Investment Management LLC Sells 135,784 Shares of Artivion, Inc. $AORT

GW&K Investment Management LLC cut its holdings in Artivion, Inc. (NYSE:AORT) by 13.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 843,907 shares of the company’s stock after selling 135,784 shares during the period. GW&K Investment Management LLC owned about 1.79% of Artivion worth $35,731,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in AORT. Champlain Investment Partners LLC acquired a new stake in Artivion in the 3rd quarter valued at $17,912,000. Quantbot Technologies LP bought a new position in shares of Artivion in the 3rd quarter valued at about $234,000. Aster Capital Management DIFC Ltd increased its position in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the last quarter. Vanguard Group Inc. raised its holdings in Artivion by 8.3% during the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after acquiring an additional 232,424 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Artivion by 338.2% during the third quarter. JPMorgan Chase & Co. now owns 122,199 shares of the company’s stock valued at $5,174,000 after purchasing an additional 94,312 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Price Performance

NYSE:AORT opened at $37.87 on Friday. The firm’s fifty day moving average price is $41.24 and its two-hundred day moving average price is $42.88. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. The company has a market cap of $1.81 billion, a P/E ratio of 189.36 and a beta of 1.60. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.25.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.14 by $0.03. The business had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s revenue was up 19.2% compared to the same quarter last year. Equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Wall Street Analyst Weigh In

AORT has been the topic of a number of analyst reports. Weiss Ratings upgraded Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Canaccord Genuity Group cut their price target on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Finally, Citizens Jmp upped their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.47.

Insider Activity at Artivion

In other Artivion news, CEO James P. Mackin sold 20,962 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $787,961.58. Following the transaction, the chief executive officer owned 780,031 shares in the company, valued at $29,321,365.29. This trade represents a 2.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean F. Holloway sold 8,962 shares of Artivion stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $38.00, for a total value of $340,556.00. Following the sale, the senior vice president directly owned 185,095 shares of the company’s stock, valued at $7,033,610. This represents a 4.62% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 137,615 shares of company stock valued at $5,180,246 in the last 90 days. Corporate insiders own 7.60% of the company’s stock.

Key Headlines Impacting Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Quarterly results beat expectations (EPS and revenue) and showed ~19% YoY revenue growth, supporting the growth narrative and analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where guidance, commercialization updates or product milestones could be disclosed and re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with elevated price targets), which helps sentiment but may already be priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite — useful narrative fuel but not an immediate catalyst. Kalkine – Portfolio Expansion Article
• Negative Sentiment: Clustered insider selling March 2–4: CEO James Mackin sold 17,887 shares (~$676k), EVP Lance Berry sold ~6,316 shares (~$238k), other senior execs (SVPs, CAO Amy Horton and others) sold multiple tranches. Markets often interpret concentrated senior‑level sales as a negative near‑term signal despite insiders retaining large stakes. See filings and coverage. SEC Form 4 – Mackin Benzinga – CCO Trade Benzinga – Lance Berry Sale

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.